8-K/ALeadership ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K/A Report, Executive Changes (Dec 11, 2019)

Filed December 11, 2019For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K/A amendment on December 10, 2019, primarily to update information regarding board committee appointments. This filing confirms that as of December 5, 2019, Michael Bonney was appointed to the Audit Committee and the Integration Committee, Dr. Julia A. Haller joined the Science & Technology Committee, and Phyllis Yale was appointed to the Committee on Directors and Corporate Governance. These appointments follow their election to the Board of Directors, effective November 20, 2019, which also resulted in an increase in the Board's size to fourteen members. While this amendment does not introduce new material financial events or strategic shifts, it provides clarity on the governance structure and committee assignments for the newly elected directors. Investors should view these changes as routine adjustments to the company's board composition aimed at ensuring effective oversight and management of key operational areas, particularly as the company integrates recent significant transactions. The increase in board size suggests a commitment to comprehensive expertise and a diversified governance approach.

Key Highlights

  • 1Board committee appointments made for new directors Michael Bonney, Dr. Julia A. Haller, and Phyllis Yale.
  • 2Michael Bonney appointed to Audit Committee and Integration Committee.
  • 3Dr. Julia A. Haller appointed to Science & Technology Committee.
  • 4Phyllis Yale appointed to Committee on Directors and Corporate Governance.
  • 5Board of Directors size increased to fourteen members.
  • 6Appointments are a follow-up to the election of these directors effective November 20, 2019.

Frequently Asked Questions

The primary purpose of this 8-K/A filing is to report on the appointments of newly elected directors to specific board committees and to update the overall size of the Board of Directors.

Michael Bonney, Dr. Julia A. Haller, and Phyllis Yale have been appointed to various board committees. Specifically, Michael Bonney to Audit and Integration, Dr. Julia A. Haller to Science & Technology, and Phyllis Yale to Directors and Corporate Governance.

This filing reflects an expansion of the Board of Directors to fourteen members and formalizes the committee assignments for the newly elected directors, indicating a strengthened governance structure with specialized oversight roles.

This amendment is primarily administrative and concerns board composition and committee appointments. It does not appear to introduce any new material financial events or direct financial impacts for investors.